Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma

Jaffer A. Ajani; James L. Abbruzzese; Avi B. Markowitz; Yehuda Z. Patt; Karen Daugherty

doi:10.1007/BF00873914

Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma

Jaffer A. Ajani, James L. Abbruzzese, Avi B. Markowitz, Yehuda Z. Patt, Karen Daugherty

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m² intravenously on days 1-5 and alpha-interferon at 5 million units/m² subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

Original language	English (US)
Pages (from-to)	67-69
Number of pages	3
Journal	Investigational New Drugs
Volume	11
Issue number	1
DOIs	https://doi.org/10.1007/BF00873914
State	Published - Feb 1993

Keywords

alpha-interferon
colorectal carcinoma
etoposide

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00873914

Cite this

@article{43be525527f540a0aed02d662ddc616d,

title = "Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma",

abstract = "Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.",

keywords = "alpha-interferon, colorectal carcinoma, etoposide",

author = "Ajani, {Jaffer A.} and Abbruzzese, {James L.} and Markowitz, {Avi B.} and Patt, {Yehuda Z.} and Karen Daugherty",

year = "1993",

month = feb,

doi = "10.1007/BF00873914",

language = "English (US)",

volume = "11",

pages = "67--69",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma

AU - Ajani, Jaffer A.

AU - Abbruzzese, James L.

AU - Markowitz, Avi B.

AU - Patt, Yehuda Z.

AU - Daugherty, Karen

PY - 1993/2

Y1 - 1993/2

N2 - Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

AB - Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

KW - alpha-interferon

KW - colorectal carcinoma

KW - etoposide

UR - http://www.scopus.com/inward/record.url?scp=0027195834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027195834&partnerID=8YFLogxK

U2 - 10.1007/BF00873914

DO - 10.1007/BF00873914

M3 - Article

C2 - 8349439

AN - SCOPUS:0027195834

SN - 0167-6997

VL - 11

SP - 67

EP - 69

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this